Christopher Counter

Christopher Counter

Company: Duke University

Job title: Professor


Interrogating the RAS Interactome for New Therapeutic Opportunities 3:30 pm

Combining proximity labelling with CRISPR/Cas9 loss-of-function screening identified the interactomes of each RAS isoform Mining these datasets for isoform-specific interactions identified PIP5K1A as specifically binding to and promoting oncogenic KRAS, but not NRAS or HRAS signalling and transformation, providing a new therapeutic opportunity Mining these datasets for the top dependency identified EFR3A as a new…Read more

day: Day Two Track D

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.